MARKET

ACRS

ACRS

Aclaris Therapeutics Inc
NASDAQ
4.520
-0.020
-0.44%
After Hours: 4.520 0 0.00% 18:25 05/22 EDT
OPEN
4.540
PREV CLOSE
4.540
HIGH
4.600
LOW
4.495
VOLUME
627.71K
TURNOVER
--
52 WEEK HIGH
5.15
52 WEEK LOW
1.220
MARKET CAP
631.28M
P/E (TTM)
-8.0657
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACRS last week (0511-0515)?
Weekly Report · 5d ago
Aclaris Therapeutics (ACRS) Gets a Buy from Piper Sandler
TipRanks · 05/11 11:55
Guggenheim Keeps Their Buy Rating on Aclaris Therapeutics (ACRS)
TipRanks · 05/11 11:52
Aclaris Therapeutics: Advancing Immunology Pipeline and Strong Cash Position Support Reiterated Buy, Unchanged $16 Price Target
TipRanks · 05/11 10:26
Weekly Report: what happened at ACRS last week (0504-0508)?
Weekly Report · 05/11 09:07
Analysts Offer Insights on Healthcare Companies: Medline (MDLN), Aclaris Therapeutics (ACRS) and Alkermes (ALKS)
TipRanks · 05/11 02:41
Analysts’ Top Healthcare Picks: Silence Therapeutics (SLN), Aclaris Therapeutics (ACRS)
TipRanks · 05/08 17:20
Aclaris Therapeutics (ACRS) Gets a Buy from Oppenheimer
TipRanks · 05/08 12:59
More
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).

Webull offers Aclaris Therapeutics Inc stock information, including NASDAQ: ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.